 UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 GLOBE NEWSWIRE -- In a release issued under the same headline earlier today by LAVA Therapeutics N.V. Nasdaq: LVTX, please note that in the second paragraph Vγ9Vδ2 T cells were incorrectly written as V9V2 T cells. The corrected release follows: 